Singapore is in the process of rolling out the vaccination program, which started with frontline healthcare professionals and senior citizens. During the course of this programme, it is expected to cover the majority of the population living in Singapore.
The rise in community cases has currently put Singapore back on high alert with the government encouraging everyone to register for vaccinations. Influx of variants of the virus emerging within the country and in the region has led to much public discourse as well and many have been considering whether getting vaccinated is suitable for them or not.
In this context and the exceedingly polarised global debate around vaccines in general and COVID-19 vaccination in particular, there is a real risk that people may be making vaccination decisions based on incorrect, insufficient or irrelevant information.
To combat this and to support the Ministry of Health Singapore in its vaccination drive, the EuroCham Healthcare committee in partnership with Fresenius Medical Care are proud to bring together a variety of stakeholders to discuss the issues related to COVID-19 vaccination and provide clarity of facts to combat inaccurate information or misperceptions in the public domain.
4.45 pm Webinar Waiting Room Opens
5.00 pm Opening Remarks by Mr Federico Donato, President of EuroCham
5.05 pm Welcome Remarks by Mr Anbu Srinivasan, Chair of EuroCham’s Healthcare Committee
5.10 pm Dr Michael Etter, Senior Vice President, Medical Office, Fresenius Medical Care
– “COVID-19 management in high-risk populations – what arrows do you have in your quiver?“
5:25 pm Dr Amgad Gamil, Senior Director, Medical & Scientific Affairs, Emerging Markets, Vaccines, Pfizer
5.35 pm Dr Sanjoy Datta, Vice President Medical & Clinical – Greater China & Intercontinental, GSK Vaccines
– “As variants continue to emerge, what impact does this have on currently available vaccines and interventions? And as the COVID-19 pandemic moves to it being “endemic”, what implications does this have for future vaccine and treatment development?“
5.45 pm Moderated Panel Discussion and Q&A by Professor John Lim, Executive Director, Centre of Regulatory Excellence, Duke-NUS Medical School
– Dr Michael Etter, Senior Vice President, Medical Office, Fresenius Medical Care
– Dr Amgad Gamil, Senior Director, Medical & Scientific Affairs, Emerging Markets, Vaccines, Pfizer
– Dr Sanjoy Datta, Vice President Medical & Clinical – Greater China & Intercontinental, GSK Vaccines
– Professor Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health
– Mr Simon Gordon, Chief Commercial Officer, Accredify
6.25 pm Closing Remarks
Dr Michael Etter joined Fresenius Medical Care Asia Pacific in 2009, leading the Medical Office and the Medical Affairs departments.
As a chief medical officer, Dr Etter oversees all medical aspects of the medical device and pharmaceutical business segments as well as the healthcare services provided in dialysis clinics, hospitals, and other medical institutions within the Asia Pacific.
In addition to medical support related to CKD and ESKD across the portfolio of healthcare services and products provided in Asia, Dr Etter’s clinical focus is on critical care medicine and related extracorporeal therapies. He holds board certifications in surgery, emergency medicine, and medical quality management. He is a graduate of the Technical University Munich Medical School in Germany and holds dual master’s degrees in business administration and public health.
Amgad Gamil, M.B.B.Ch., MBA, is a Senior Director in the Emerging Markets Medical and Scientific Affairs of vaccines in Pfizer Inc. He is currently the Regional Medical Lead for Asia Region for Vaccines & the Emerging Markets Medical Lead for C. difficile vaccine at Pfizer Inc. His group is part of the Emerging Markets Medical and Scientific Affairs Group in Pfizer Vaccines and he is based in Dubai, United Arab Emirates.
Dr Gamil received his medical degree in medicine and surgery from Ain Shams University School of Medicine in Cairo, Egypt, and a master’s degree in paediatrics from the same university. He received a Professional Certificate in Pharmaceutical Marketing from the American University in Cairo, followed by a Marketing Diploma from the Marketing Improvement Group-PLC in London, United Kingdom. Dr Gamil earned a Master of Business Administration degree from City University in the United States. He was also an instructor at the American University in Cairo.
For the past 25 years, Dr Gamil has worked in the pharmaceutical & research industry in various senior management roles in medical affairs, clinical research and development, safety, business development, marketing and training functions in-country, regional, emerging markets and global levels. He has a lot of publications in vaccines and other therapeutic areas, either as an author, or co-author.
Dr Sanjoy Datta currently leads all Medical, Clinical and Scientific activities for GSK Vaccines in the Greater China & Intercontinental region. His role enables him to facilitate the introduction and uptake of GSK’s vaccines in the many settings of Asia-Pacific.
Dr Sanjoy Datta graduated from the University of Bristol Medical School in 1992 and completed his housemanship in England. He then returned to Singapore and joined the Ministry of Health, before completing his compulsory National (Military) Service as a Medical Officer with the Singapore Army.
In 2001, he embarked on a Master of Public Health program at Johns Hopkins University School of Public Health, graduating the following year with special certifications in Vaccines Science & Policy and Health Finance & Management. He then joined GlaxoSmithKline and has over the years served in various roles for the Vaccines organization at local, regional and global levels, with responsibilities for external interactions, business leadership, clinical development and governance. He has been based in Singapore, Mumbai and Brussels (at GSK Vaccines’ headquarters).
Dr Li Yang Hsu is an infectious diseases physician who is currently Vice Dean of Global Health and Head of the Infectious Diseases Programme at Saw Swee Hock School of Public Health, National University of Singapore (NUS). He is also Associate Director of the Singapore Centre for Environmental Life Sciences Engineering, a Research Centre of Excellence on biofilms and microbial communities based jointly at Nanyang Technological University and NUS. Although he has been involved in COVID-19 research and education, his primary academic focus is in the area of antimicrobial resistance. He has worked with famed comic book artist Sonny Liew to publish educational comics on both COVID-19 and antimicrobial resistance.
Mr Gordon leads Accredify’s commercial activities including the Company’s healthcare business. Accredify specialises in issuing digital, easily verifiable documents and since May 2020 have been heavily involved in Singapore’s response to COVID-19. Accredify first started issuing COVID-19 Discharge Memos on behalf of Singapore’s Ministry of Health and are now focussed on digital, easily verifiable COVID-19 test results and vaccination records in 8 APAC markets. To date, Accredify has issued over 600,000 COVID-19 related medical records that have been verified over 6 million times.
COVID-19 compliance is a long-term requirement and many stakeholders require an automated workflow with high levels of assurance. Accredify serves governments, travel and healthcare partners who want to implement or be a part of these emerging digital workflows.
Prior to Accredify, Mr Gordon worked in Venture Capital at SGInnovate where he invested in and built early-stage medical and healthcare-related tech startups. Mr Gordon also worked as a Management Consultant focused on early-stage MedTech and digital healthcare ventures. Through this work, Mr Gordon has experience advising multinational corporations in licensing or acquiring early-stage technology. Mr Gordon graduated with a Masters of Bioscience Enterprise and a Bachelor of Science in Neuroscience. His research focused on the monetisation of early-stage technology as well as the underlying neuroendocrinology of postpartum depression.
Professor John CW Lim is founding Executive Director of the Centre of Regulatory Excellence (CoRE) at the Duke-National University of Singapore Medical School (Duke-NUS), inaugural Chairman of the Consortium for Clinical Research & Innovation Singapore (CRIS), Senior Advisor at Singapore’s Ministry of Health (MOH), and Policy Core Lead at the SingHealth Duke-NUS Global Health Institute (SDGHI). He is a Professor of Practice at Duke-NUS and the NUS Saw Swee Hock School of Public Health.
Formerly, Chief Executive Officer of Singapore’s Health Sciences Authority and Deputy Director of Medical Services (Industry & Research Matters) in MOH, Professor Lim has also held other senior positions in Singapore’s Health and Education ministries. His current roles promote capacity building and scientific excellence for health product regulation, health policies, and systems in Southeast Asia and the Asia-Pacific.
Professor Lim is a member of the Singapore Food Agency Board, APEC Life Sciences Innovation Forum’s Executive Board, Davos Alzheimer’s Collaborative Leadership Group, US Pharmacopoeia (USP) Council of the Convention as Asia-Pacific Chapter Chair, USP Quality Institute’s Advisory Group, Centre for Innovation in Regulatory Science’s Scientific Advisory Council, and St Andrew’s Mission Hospital Board.
Student tickets are available for this event.
Students from partnering universities are invited to join, free of charge. Partnering universities; NUS, NTU, SMU, EDHEC, ESSEC & INSEAD.
There are limited student tickets available and are subject to correct registration details.
- Please sign up with your university-issued email address
- Enter your institution under “company”
- Enter your major/ programme under “designation”
- Select “Complimentary Student Ticket”
Registration Guidelines –
Please follow these simple steps for easy registration to our webinar.
Step 1: Register below. You will receive an automated registration confirmation email from EuroCham.
Step 2: Prior to the event, a Zoom link will be sent 24 hours before the event. Please watch out for this second email.
Step 3: Using the link provided in the second email, click on the link 15 minutes prior to the start of the event.
Step 4: We will only admit attendees whose Zoom profiles match their registration names, so please make sure that your Zoom profile corresponds with your registration name.
Thank you for your understanding.
The organisers reserve the right to change the programme content without giving prior notification or any reasons thereof.